Fetal Macrosomia Market Research Report -Forecast till 2030

Fetal Macrosomia Market Growth And Trends Analysis By Diagnosis (Ultrasound, Antenatal Testing, And Others), By Treatment (Medical Care, Surgical Care, And Others), By End User- Forecast Till 2030

ID: MRFR/Pharma/2685-HCR | 79 Pages | Author: Rahul Gotadki | March 2024         

Fetal Macrosomia Market Speak to Analyst Request a Free Sample

Market synopsis of Fetal Macrosomia Market:


The Fetal Macrosomia Market is expected to reach USD 4,826.2 Million by 2030 at 7.6% CAGR during the forecast period 2022-2030.


Fetal macrosomia is described as a medical condition in which baby is significantly larger than average before birth. The average birth weight of babies is seven pounds. The possible signs and symptoms of macrosomia are large fundal height and excessive amniotic fluid (polyhydramnios). The most common causes of macrosomia are genetic, maternal conditions such as diabetes or obesity, jaundice, respiratory distress, exceptionally the infant might have some medical conditions which may be responsible for accelerating the fetal growth. Some major risk factors related to macrosomia are injury to new born such as shoulder dystocia.

The babies with macrosomia have a birth weight more than 8 pounds, 13 ounces (4,000 grams). Approximately 9% of babies born weigh more than 8 pounds, 13 ounces. Fetal macrosomia occurs in around 10% of all pregnancies in the US. Increasing occurrence of macrosomia is a key factor for market growth. Increasing awareness play an important role in the growth of fetal macrosomia market. Macrosomia birth may leads to various medical complications.

Increasing demand of accurate diagnosis and treatment from emerging markets of Asia and South America is major driving force of this market. Healthcare sector is rapidly changing in this region due to various factors such as technological advancement and increasing healthcare expenditure.

Pharmaceutical companies, medical research centers and hospitals are working on effective cure for fetal macrosomia by investing large amount of money and resources for R&D. Introduction of advanced diagnostic tools are another important factor for the market growth.

FIGURE 1    GLOBAL FETAL MACROSOMIA MARKET SHARE BY DIAGNOSIS, 2016 (%)

Fetal Macrosomia Market  Share 


Sources: National Center for Biotechnology Information, SA Health, U.S. National Library of Medicine, Directorate of Industries, Annual report, White paper, Company Presentation


Key players for global fetal macrosomia market:      


Some of the key players in this market are: Carestream Health (US),  Esaote SpA (Italy),  Fonar Corporation (US),  Fujifilm Holdings Corporation (Japan),  GE Healthcare (UK),  Hitachi Medical Corporation (Japan),  Hologic, Inc. (US),  Philips Healthcare (Netherlands),  Samsung Medison Co. Ltd (Republic of Korea),  Shimadzu Corporation (Japan),  Siemens Healthcare (Germany),  Toshiba Corporation (Japan),) and others.


Fetal Macrosomia Market Segments:


Global Fetal macrosomia market has been segmented on the basis of diagnosis which comprise of ultrasound, antenatal testing, and others. Ultrasound is further sub-segmented into standard ultrasound, transvaginal scan, fetal echocardiography, 3-d ultrasound, dynamic 3-d ultrasound, and others. Antenatal testing is further sub-segmented into blood and urine tests, amniocentesis, chorionic villus sampling, and others.


On the basis of treatments, the market has been segmented into medical care, surgical care, and others. Surgical Care is sub-segmented into cesarean delivery, and others.


On the basis of end user, it is segmented into hospital and clinics, medical research centers, academic institutes, and others.


Research Methodology:


Fetal Macrosomia Market  Outlook

 Sources: National Center for Biotechnology Information, SA Health, U.S. National Library of Medicine, Directorate of Industries, Annual report, White paper, Company Presentation


 Regional Analysis of Fetal Macrosomia Market:  


Considering the global scenario of the fetal macrosomia market, Americas is the largest market for fetal macrosomia. The Americas mainly include North America and South America, out of which North America is holding majority of market share of this region. US is the top revenue generating market in North America. Various factors are leading the market growth such as availability of advanced diagnostic and treatment options, funding for research and clinical trials etc. South America fetal macrosomia market is also growing significantly and mainly includes Brazil, Argentina and Chile.  Europe is another important market for fetal macrosomia. Increasing incidence of fetal macrosomia is a major driving force of this market. Europe is mainly divided into Eastern Europe and Western Europe. West European countries like Germany, UK and France are dominating this market while East European region is also growing significantly. Asia Pacific region is showing the fastest growth rate in global fetal macrosomia market due to some major factors such as developing healthcare facilities, increasing awareness, and changing healthcare facilities. China is holding major market share while India fetal market is expected to have fastest growth in this region. Government initiatives to increase awareness plays important role in the growth of this market. Middle East & Africa is expected to have a limited growth due to lack of knowledge of disorders, traditional healthcare practices etc. Middle East region is dominating this market due to some major factors like developed healthcare facilities and government support to improve public health.


The report for Global Fetal Macrosomia Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions 


Intended Audience:



  • Fetal macrosomia diagnostic and treatment supplies companies

  • Fetal macrosomia diagnostic and treatment supplies providers

  • Medical research laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


 

Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 4,826.2 Million
  CAGR   2022-2030: ~7.6%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment And End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Samsung Medison Co. Ltd, Shimadzu Corporation, Siemens Healthcare, Fonar Corporation, Philips Healthcare, Fujifilm Holdings Corporation, Hitachi Medical Corporation, Carestream Health, Esaote SpA, Hologic, Inc., Toshiba Corporation, and GE Healthcare
  Key Market Opportunities ·  Americas is the largest revenue generating market for fetal macrosomia·  Asia Pacific region is showing the fastest growth rate in global fetal macrosomia market due to some major factors such as developing healthcare facilities, increasing awareness, and changing healthcare facilities.
  Key Market Drivers   High demand for accurate diagnosis of the disease at a preventive stage in Asia and South America is the major driver
 



Frequently Asked Questions (FAQ) :

fetal macrosomia market can expand at 7.6% CAGR from 2022 to 2030.

fetal macrosomia market is predicted to be valued at USD 4,826.2 Million by 2030.

High demand for accurate diagnosis of the disease at a preventive stage in Asia and South America is the major driver of the global fetal macrosomia market.

The Americas can dominate the global fetal macrosomia market due to increasing awareness among the populace and availability of advanced diagnostic solutions.

APAC is the region in the global fetal macrosomia market.

Samsung Medison Co. Ltd, Shimadzu Corporation, Siemens Healthcare, Fonar Corporation, Philips Healthcare, Fujifilm Holdings Corporation, Hitachi Medical Corporation, Carestream Health, Esaote SpA, Hologic, Inc., Toshiba Corporation, and GE Healthcare are notable players of the global fetal macrosomia market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid